Akari Therapeutics Plc - ADR

NASDAQ:AKTX  
0.54
+0.01 (+1.64%)
Earnings Announcements

Akari Therapeutics Reports Second Quarter 2022 Financial Results And Highlights Recent Pipeline Progress

Published: 09/27/2022 13:43 GMT
Akari Therapeutics Plc - ADR (AKTX) - Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress.
Akari Therapeutics - Phase 3 Part a Clinical Trial of in Severe Pediatric Hsct-tma Remains on Track for Expected Data Readout in H1 of 2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.07

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.06

More details on our Analysts Page.